Vraylar (Cariprazine) is More Appropriate for Bipolar Depression
Based on the most recent and highest quality evidence, Vraylar (cariprazine) is the more appropriate choice for bipolar depression compared to Rexulti (brexpiprazole), as cariprazine has FDA approval and robust clinical trial evidence specifically for bipolar depression, while brexpiprazole lacks FDA approval for this indication and has only limited pilot study data. 1
Evidence Supporting Cariprazine for Bipolar Depression
FDA Approval and Guideline Support
Cariprazine is FDA-approved for depressive episodes in bipolar I disorder 1, and is consistently listed as a first-line treatment option in the most recent 2026 clinical practice guidelines 2. The recommended dosing for bipolar depression is 1.5-3 mg/day 2.
High-Quality Efficacy Data
The 2026 BMJ umbrella review demonstrates cariprazine's efficacy across all key outcomes in bipolar depression with high to moderate certainty evidence 3:
- Symptom reduction: eSMD 0.23 (95% CI 0.06-0.4), high certainty
- Response rate: eSMD 0.25 (95% CI 0.1-0.4), high certainty
- Remission rate: eSMD 0.23 (95% CI 0.08-0.39), moderate certainty
This places cariprazine among the select few agents with robust evidence across the full spectrum of bipolar depression outcomes.
Efficacy in Mixed Presentations
A critical advantage of cariprazine is its demonstrated efficacy in bipolar depression with concurrent manic symptoms 4. Post-hoc analysis of three randomized trials showed significant improvement in patients with mixed features, with higher doses (3 mg/day) potentially more effective when manic symptoms are present 4. This is particularly relevant since mixed presentations are common and difficult to treat.
Limited Evidence for Brexpiprazole in Bipolar Depression
Lack of FDA Approval
Brexpiprazole is not FDA-approved for bipolar depression 5, 6. It is only approved for schizophrenia and as augmentation in major depressive disorder—not for bipolar disorder treatment.
Minimal Clinical Trial Data
The evidence for brexpiprazole in bipolar depression consists of:
- One small pilot study (N=21) with open-label design 7
- No placebo-controlled trials
- No inclusion in major treatment guidelines as a recommended option for bipolar depression
The 2019 pilot study showed reduction in depressive symptoms, but the open-label design and small sample size provide insufficient evidence to support its use as a standard treatment option 7.
Clinical Decision Algorithm
For bipolar depression treatment:
First-line options (in order of evidence strength):
- Quetiapine 300-600 mg/day
- Lurasidone 40-120 mg/day
- Cariprazine 1.5-3 mg/day
- Olanzapine-fluoxetine combination 2
Consider cariprazine specifically when:
Brexpiprazole should not be used as it lacks evidence and approval for bipolar depression
Important Caveats
Akathisia Risk
Cariprazine carries a higher risk of akathisia compared to placebo and some other atypical antipsychotics 9. Monitor closely and consider dose reduction or adjunctive beta-blockers if akathisia emerges.
Metabolic Profile
While cariprazine has a favorable metabolic profile compared to olanzapine 9, routine metabolic monitoring remains important as with all atypical antipsychotics.
Long Half-Life
Cariprazine has an extremely long half-life (weeks due to active metabolites) 1. This means:
- Effects may take longer to manifest fully
- Side effects may persist after discontinuation
- Dose adjustments should be made cautiously with adequate time between changes
Real-World Effectiveness
A 2026 real-world study showed cariprazine had 37% lower manic events and 28% lower depressive events compared to aripiprazole in bipolar I disorder patients 8, supporting its full-spectrum efficacy across both mood poles.
The evidence unequivocally supports cariprazine over brexpiprazole for bipolar depression based on FDA approval, guideline recommendations, high-certainty efficacy data, and demonstrated effectiveness in mixed presentations.